compared the renovascular effects of telmisartan and amlodipine in hypertensive patients with chronic kidney disease and mild renal insufficiency. Among other results, a significant increase in carotid intima-media thickness (IMT) was demonstrated in the amlodipine group after 12 months of treatment as compared to baseline values. In the telmisartan group, however, the investigators found a significant IMT regression; as they commented, it remains to be determined whether this regression is specific to telmisartan or constitutes a class effect of angiotensin-II receptor blockers (ARBs).
Letter to the Editor

Telmisartan and Carotid Intima-Media
Thickness Regression: A Class Effect of Angiotensin-Receptor Blockers?
To the Editor:
We read with great interest the article by Dr. Nakamura et al. that was recently published in Hypertension Research (1) . In this paper, the authors compared the renovascular effects of telmisartan and amlodipine in hypertensive patients with chronic kidney disease and mild renal insufficiency. Among other results, a significant increase in carotid intima-media thickness (IMT) was demonstrated in the amlodipine group after 12 months of treatment as compared to baseline values. In the telmisartan group, however, the investigators found a significant IMT regression; as they commented, it remains to be determined whether this regression is specific to telmisartan or constitutes a class effect of angiotensin-II receptor blockers (ARBs).
Previous studies on the effect of ARBs on IMT have yielded conflicting results. In 2002, the LAARS study enrolled 280 hypertensive patients that were randomized to receive losartan (50 mg) or atenolol (50 mg) for 24 months and demonstrated a significant annual IMT decrease of 0.038±0.004 mm in the losartan group (2) . Similarly, Tedesco et al. demonstrated a significant IMT regression after 24 months of losartan treatment (3). Moreover, Olsen et al. (4) and Sonoda et al. (5) showed that losartan resulted in a significant IMT decrease (0.83±0.11 to 0.79±0.16 mm and 0.87±0.14 to 0.79±0.16 mm, respectively) in hypertensive patients within 3 and 1 years of treatment, respectively. In contrast, losartan failed to induce a significant IMT regression within 12 months of treatment in a study by UchiyamaTanaka et al. (6) .
As in the losartan trials, studies on the effect of candesartan on IMT have yielded conflicting results. Ariff et al. (7) and Ono et al. (8) demonstrated that candesartan leads to a significant IMT reduction of 0.05 mm and 0.13 mm within 12 and 24 months respectively. However, these findings were not confirmed by Ichihara et al., who showed that IMT remained unchanged when candesartan was added in patients already receiving calcium channel blockers (9). Similarly, candesartan did not induce a significant IMT regression in a study by Tomás et al. (10). However, this study was underpowered to identify a beneficial effect of candesartan on IMT since it involved a small sample size (n= 34) and lasted only 3 months.
Valsartan has been shown not to induce IMT regression. In a recent article by Okura et al., valsartan (80-160 mg) did not influence IMT after 24 months of treatment (11). Similar results were demonstrated in a study by Kosch et al., but that study followed patients for only 3 months (12). On the other hand, treatment with irbesartan in the SILVHIA study resulted in a significant IMT reduction compared with atenolol, which was used as control (13).
The conflicting results of the aforementioned studies raise serious concerns as to whether the beneficial effect of telmisartan on IMT shown by Nakamura et al. (1) 
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To the Editor: As Dr. Ntaios et al. have suggested, it is important to consider whether the beneficial effect of telmisartan on intima-media thickness (IMT) is a class effect of angiotensin receptor blockers (ARBs). Telmisartan has the unique property of being a peroxisome proliferator-activated receptor (PPAR)-γ activator. We have recently proposed classifying telmisartan as a "metabolic sartan" (1) . To reduce cardiovascular mortality or morbidity, more intense effort should be focused on aggressively modifying risk factors atnd the early stage of vascular failure (1) . We believe that telmisartan has different properties for targeting vascular failure. Recently, Grassi et al. (2) reported that telmisartan 1) is effective in favoring the regression of cardiac and vascular organ damage, 2) reduces arterial stiffness and improves vascular distensibility and 3) reverses the endothelial dysfunction typical of the hypertensive state, particularly when complicated by chronic kidney disease (CKD) or metabolic syndrome. Telmisartan Randomized Assessment Study in ACE-I Intolerant Patients with Cardiovascular Disease (TRANSCEND) Investigators (3) have reported that telmisartan was well tolerated in patients unable to tolerate angiotensin-converting enzyme (ACE) inhibitors, and that it modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction, or stroke. Few studies have compared various ARBs in renovascular protection, including IMT in CKD patients. Recently, Ohtake et al. (4) reported that ARB monotherapy can significantly reverse pathological changes in chronic glomerulonephritis. Bakris et al. (5) reported that telmisartan is superior to losartan in reducing proteinuria in hypertensive diabetic nephropathy patients. We are now studying the effects of various ARBs on renovascular protection, including IMT, to determine whether ARBs show a class effect in hypertensive CKD patients. In any event, establishing the effect of telmisartan on IMT will require a large-scale clinical trial designed to compare it with other ARBs. 
